WATCH LIVE
timothy sykes logo
MRNA Stock Surges As Flu Win And CAR-T Plans Ignite Momentum Thumbnail
G Google News

MRNA Stock Surges As Flu Win And CAR-T Plans Ignite Momentum

JACK KELLOGG•UPDATED JUL. 2, 2026, 5:04 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 10.57 percent amid optimism over promising late-stage vaccine trial results.

Key Takeaways For MRNA Traders

  • FDA advisers unanimously backed Moderna’s mRNA-1010/mFLUSIVA flu shot for adults 50–64 and 65+, supporting its Biologics License Application ahead of an 2026/08/05 PDUFA decision.
  • Regulatory backing for mFLUSIVA drove roughly a 4% intraday pop in MRNA, signaling traders are starting to price in a new flu revenue stream.
  • Jefferies kept a Hold and $45 target on MRNA, seeing flu upside but not expecting major revenue contributions until around 2027.
  • Piper Sandler raised its MRNA target to $77 and reiterated Overweight as the stock pushed into the mid-$60s, reflecting rising optimism on upside potential.
  • Moderna’s Science Day and in vivo CAR-T plans highlighted a broadening mRNA platform across oncology, autoimmune disease, infectious disease, and rare disorders.

Candlestick Chart

Live Update At 17:03:38 EDT: On Thursday, July 02, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 10.57%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has ripped higher on the chart. In mid-June it was trading around the high-$40s and low-$50s. By 2026/07/02, Moderna stock opened at $73.71 and closed at $79.76, after touching $81.40. That’s a huge trend move in just a few weeks.

Intraday, MRNA has been acting like a momentum name again. The 5‑minute tape shows a strong morning push from the low‑$70s into the low‑$80s, then a steady grind near $79–$80 into the close. That tells traders dip buyers are in control, and late-day selling pressure is limited — classic bullish action.

Fundamentally, Moderna is still a story stock. Revenue for the latest quarter was about $389M, while total revenue over the trailing period is roughly $1.94B, way down versus the COVID boom years. Profitability metrics are ugly right now, with EBITDA around -$1.28B and free cash flow near -$692M.

More Breaking News

But MRNA sits on solid liquidity. Cash, cash equivalents, and short‑term investments total about $5.21B, with a current ratio of 2.4 and low debt (total debt to equity about 0.17). For traders, that means the company has runway to fund its mRNA pipeline, even while bleeding cash.

Why Traders Are Watching MRNA Right Now

MRNA has regained the one thing that matters most for short-term trading: a clear catalyst stack. The big spark was the FDA advisory committee’s unanimous 9–0 vote that Moderna’s mRNA‑1010 flu vaccine, branded mFLUSIVA, has a favorable benefit–risk profile in adults 50–64 and 65+. When an FDA panel goes unanimous on a late‑stage asset, traders pay attention.

That vote backs Moderna’s Biologics License Application and sets up a key PDUFA decision date on 2026/08/05. For MRNA, this is more than just another label. It’s a path to diversify away from a shrinking COVID franchise and into the massive seasonal flu market. The Street connected the dots quickly — FDA advisers also supported full approval for adults 50–64 and accelerated approval for those 65+, and the stock jumped about 4% intraday on the news.

The momentum did not stop there. MRNA shares then spiked 8.7% in one sharp intraday move to $64.95, followed by a 14.2% surge to $68.23 in the latest session mentioned, even when one of those bursts lacked fresh headlines. That kind of follow‑through says traders are now front‑running a re‑rating story.

At the same time, MRNA’s Science Day reset the narrative. Moderna showcased four already‑approved products, a growing infectious disease franchise, and pipeline breadth that reaches into oncology, autoimmune disease, and rare disorders. Validated T‑cell engager data in multiple myeloma (mRNA‑2808), an ovarian cancer follow‑on (mRNA‑2151), and plans to start clinical development of the in vivo CAR‑T candidate mRNA‑6007 in 2027 gave traders a view of what “post‑COVID Moderna” might look like.

Analysts responded. Piper Sandler boosted its MRNA price target from $69 to $77 and reiterated Overweight, even as the stock traded in the low‑to‑mid‑$60s. Another note highlighted that the broader analyst crowd still sits at an average Hold with a mean target around $48.25. That gap between bullish calls and cautious consensus is exactly where active traders hunt for volatility.

Conclusion

For MRNA traders, this is a textbook momentum setup built on real news, not just hype. Moderna stock has broken out from the high‑$40s to near $80 on the back of three drivers: a unanimous FDA advisory win for mFLUSIVA, visible progress in diversifying the mRNA platform, and a wave of price‑target hikes after in vivo CAR‑T plans and Science Day updates.

The fundamentals remain messy. MRNA is still posting heavy quarterly losses, with negative EBITDA around -$1.28B and free cash flow deep in the red. Flu revenues, according to Jefferies, are unlikely to be meaningful before roughly 2027. That’s why the firm kept a Hold rating and a $45 target, even after the advisory committee’s vote. Traders need to respect that not everyone is buying the long‑term story at any price.

At the same time, Moderna has a big cash cushion, low leverage, and now a credible roadmap beyond COVID. The unanimous flu panel decision and the PDUFA date in 2026 give MRNA a clear regulatory calendar. The Science Day pipeline — spanning oncology, autoimmune disease, and rare conditions — plus mRNA‑6007 for in vivo CAR‑T, offers optionality that momentum traders love.

As Tim Sykes loves to remind traders, “Discipline and cutting losses quickly are crucial to managing risk in volatile markets.” As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. MRNA is back in play, with wide ranges and heavy volume. For active traders, the edge comes from respecting the risk, tracking every catalyst, and letting the chart — not emotions — call the shots. This analysis is for educational and research purposes only, not trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”